Summary
Introduction
SuperGen is a pharmaceutical company dedicated to the discovery, development and commercialization of therapies to treat patients with cancer. Historically, the company has acquired products that were approved for market or for clinical investigation and applied additional developmental effort to expand sales or advance these products clinically towards potential approval for marketing.
Scope
- Contains corporate strategy, value chain presence and SWOT Analysis
- Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
- Includes information on suppliers/ partners, shareholding structure and key employees with biographies
Highlights
CLIMB (Computational Lead Identification Modeling Biology) is SuperGen's approach to small molecule drug discovery, which merges rapid screening of compound libraries with computational chemistry and systems biology techniques to identify drug leads that bind to target proteins.
Three compounds have been the primary focus of SuperGen's efforts: Dacogen for injection, Orathecin capsules and Nipent (pentostatin for injection). In 2006, Dacogen received approval for marketing in the US, Orathecin was withdrawn from the regulatory review process, Nipent and commercial infrastructure was sold to Mayne Pharma (Hospira).
SuperGen's pipeline includes MP470 Tyrosine Kinase Inhibitor/Rad 51 Suppressor and MP529 Aurora A Kinase Inhibitor, which are in preclinical stage of development. SuperGen has derived its revenues from product sales of Nipent and Surface Safe products, royalty from Dacogen sales by MGI Pharma and license fees.
Reasons to Purchase
- Access all the important information and analysis on the company in a single report
- Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain
- Gain access to company's adjusted five year financial data along with key ratios and market capitalization
|
Content
- Overview
- Catalyst
- Summary
- Company Structure
- Company Overview And Key Facts
- Business Description
- History
- Locations And Subsidiaries
- Company Financials
- Stock Market Performance
- P&L
- Balance Sheet
- Cash Flow
- Business Segment Performance
- Products & Services
- Marketed Products
- Pipeline Products
- Historical Product Sales
- Competitors And Strategic Business Relationships
- Key Competitors
- Key Suppliers
- Key Clients
- Shareholding Structure
- Strategy
- Company View
- Corporate Strategy
- Swot Analysis
- Overview
- Strengths
- Weaknesses
- Opportunities
- Threats
- Value Chain Analysis
- Overview
- Discovery And Product Development
- Key Employees
- List Of Key Employees
- Key Employee Biographies
- Financial And Operational Overview
- Financial And Operational Overview
- Appendix
- Ask The Analyst
- Datamonitor Consulting
- Disclaimer
- Table Of Figures
- Figure 1: Supergen - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)
- Figure 2: Supergen - Key Strategic Revenues, 2002-2006 ($ Mn)
- Table Of Tables
- Table 1: Supergen - Key Facts
- Table 2: Supergen- Other Locations And Subsidiaries
- Table 3: Supergen - Year-End Share Price And Market Capitalization, 2002-2006 ($)
- Table 4: Supergen - Key Events Impacting Share Price Performance
- Table 5: Supergen - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)
- Table 6: Supergen - Operating Cost Ratio Analysis, 2002-2006 (% Of Total Revenues)
- Table 7: Supergen - Balance Sheet, 2002-2006 ($ Mn)
- Table 8: Supergen - Cash Flow, 2002-2006 ($ Mn)
- Table 9: Supergen - Revenue Breakdown By Division, 2002-2006 ($ Mn)
- Table 10: Supergen - Marketed Products
- Table 11: Supergen - In-House Pipeline Products
- Table 12: Supergen - Historical Product Sales, 2002-2006 ($ Mn)
- Table 13: Supergen - Key Competitors
- Table 14: Supergen - Key Suppliers
- Table 15: Supergen - Key Shareholders
- Table 16: Supergen - Swot Analysis Summary
- Table 17: Supergen - Value Chain Analysis
- Table 18: Supergen - Key Employees
- Table 19: Supergen - Core Indicators
|
